Clinical assessment of serum hepcidin isoforms associated with iron homeostasis and erythropoiesis-stimulating agent response in CKD patients

Clinical assessment of serum hepcidin isoforms associated with iron homeostasis and erythropoiesis-stimulating agent response in CKD patients - Clinical assessment of serum hepcidin isoforms associated with iron homeostasis and erythropoiesis-stimulating agent response in CKD patients

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000003427

Enrollment

400

Registered

2010-04-01

Start date

2008-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CKD

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The enrolled patients who have been diagnosed as CKD.

Exclusion criteria

Exclusion criteria: These patients were excluded with severe inflammatory disease, infection, cancer, hematological disorders or blood transfusion within 4 weeks.

Design outcomes

Primary

Measure	Time frame
The relationship between the change of serum hepcidin and the responsiveness to erythropoiesis-stimulating agent	—

Secondary

Measure	Time frame
To evaluate the association of serum hepcidin, iron-related biomarker, erythropoitic activity and serum cytokine	—

Countries

Japan

Contacts

Public ContactHiroshi Kimura

Iizuka Hospital The department of nephrology

hkimurah2@aih-net.com0948-22-3800

Outcome results